Navigation Links
Medarex Announces 2008 Fourth Quarter and Year End Financial Results
Date:2/25/2009

925 Investment in Genmab 87,428 139,165 Other assets 6,812 10,985 -------- --------- $536,855 $759,860 ======== ========= Current liabilities $64,299 $81,645 Other liabilities 78,247 89,454 Convertible notes 145,430 143,505 Shareholders' equity 248,879 445,256 -------- --------- $536,855 $759,860 ======== ========= (1) Derived from the December 31, 2007 audited financial statements. For further information, refer to the financial statements and footnotes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2007.

The accompanying press release dated February 25, 2009 contains non-GAAP financial measures. The following table reconciles the non-GAAP financial measures contained in the press release to the most directly comparable financial measures prepared in accordance with GAAP. These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures prepared in accordance with GAAP.

The following reconciliation of GAAP net loss to non-GAAP net loss and GAAP net loss per share to non-GAAP net loss per share is provided as a complement to results p
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
2. Medarex to Present at the JPMorgan Small/Mid Cap Conference
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
5. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
7. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
8. Medarex Announces 2008 First Quarter Financial Results
9. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
10. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
11. Medarex Reviews Recent Highlights and Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 BESLER Consulting , ... services for hospitals, is pleased to announce that it ... of America’s Fastest-Growing Companies. The list represents the most ... independent entrepreneurs. , "It's been an exciting year ... included in this year's Inc. 5000 list,” said Jonathan ...
(Date:8/27/2014)... designed to help regulate the blood,s iron supply shows promise ... to results from the first human study of ... , the Journal of the American Society of Hematology ... blood cells are in short supply or do not function ... get enough oxygen, since there are fewer red blood cells ...
(Date:8/27/2014)... State University,s Center for Leadership in Disability (CLD) ... Maternal and Child Health Bureau of the Health ... the Autism Plan for Georgia, aimed at improving ... disorder. , In preparing for this project, CLD ... key stakeholders from across Georgia. The resulting plan ...
(Date:8/27/2014)... Cash House 's contributions to Horizons ... upkeep of the shelter including new initiatives and a wide ... the lives of each youth who walk through their door. ... for youth ages 16-25. Not only does Horizons operate as ... for the youth who come through their doors. Horizons has ...
(Date:8/27/2014)... Houston, TX (PRWEB) August 27, 2014 ... The reality is that depression has a mortality ... those with bi-polar disorder is slightly less, though it's ... of roughly 7%. In order to properly treat ... schizophrenia, and bi-polar, medication must be taken as directed. ...
Breaking Medicine News(10 mins):Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:Drug represents first potential treatment for common anemia 2Health News:Cash House a Major Supporter of Horizons for Youth 2Health News:Cash House a Major Supporter of Horizons for Youth 3Health News:MedicationDiscountCard.com now Makes Brintellix and Mental Illness Medications More Affordable with Discount Cards 2
... Kingdom recently instituted guidelines banning physicians, white coats and ... of bacteria within hospitals due to the belief that ... new study published today in the Journal of ... there is no difference in contamination of long- and ...
... - In an international Phase III randomized study, ... rapamycin (mTOR), has shown to dramatically improve progression-free ... (pNET), according to researchers from The University of ... findings were published in the latest New England ...
... Maureen Salamon HealthDay Reporter , WEDNESDAY, Feb. ... more than doubled the progression-free survival time for patients ... two new studies. In separate phase 3 trials ... sunitinib extended the survival of participants with advanced pancreatic ...
... Feb. 9 (HealthDay News) -- About one in 10 ... after. Though typically harmless, some may need treatment because ... "There are several different types of birthmarks, so it ... considering any possible treatments," dermatologist Dr. Sheila Fallon Friedlander, ...
... the National Institutes of Health envisions scientists being able ... gaining new insights into multi-gene disorders in the next ... drug targets and the development of practical treatments for ... plan from the National Human Genome Research Institute (NHGRI). ...
... PARK, Md. -- Under our feet and ubiquitous, lowly soil ... change and population growth. But in the January-February issue of ... team of scientists say soil is an essential piece of ... it. Strategies for doing so include refocusing and boosting research, ...
Cached Medicine News:Health News:Long- and short-sleeved physician workwear receive same amount of bacterial and MRSA contamination 2Health News:Everolimus improves progression-free survival for patients with rare pancreatic cancer 2Health News:Everolimus improves progression-free survival for patients with rare pancreatic cancer 3Health News:2 Experimental Drugs Show Promise for Rare Pancreatic Cancer 2Health News:2 Experimental Drugs Show Promise for Rare Pancreatic Cancer 3Health News:Not All Birthmarks Harmless, Expert Says 2Health News:NHGRI charts course for the next phase of genomics research 2Health News:NHGRI charts course for the next phase of genomics research 3Health News:NHGRI charts course for the next phase of genomics research 4Health News:Soil science: Healing our planet's ills from the ground up 2
(Date:8/27/2014)... Aug. 27, 2014 Decision Resources Group finds ... Memphis health system and hospital ... integration, with rivals Methodist Le Bonheur Healthcare and Baptist ... to coordinate patient care. In addition, a national contract ... most health plan enrollment in the Memphis ...
(Date:8/27/2014)... By now, if you haven,t heard about the ALS Ice ... awareness campaign has brought this devastating disease to the forefront ... Million (and counting) for ALS. Every day, more and more ... as well. One such company, Acorn Stairlifts Inc., ... works with ALS sufferers and helps to provide solutions for ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new ... Global Heart Valve Repair and Replacement ... About Heart Valve Repair and Replacement ... which control the flow of blood during the ... diseases such as valvular stenosis, valvular insufficiency or ...
Breaking Medicine Technology:Memphis-area Health Systems Turn Attention to Clinical Integration 2Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
12 mm diameter pigtail curved probes with eyes 4mm back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.9 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
The VISULAS 532s combines ease of use, efficiency and safety to provide ophthalmologists with an overall system sharply focused on their requirements. ,The VISULAS 532s is a laser of many talent...
Medicine Products: